- Home
- Publications
- Publication Search
- Publication Details
Title
Insulintherapie – neue Insulinanaloga
Authors
Keywords
Diabetes mellitus, Hypoglykämie, Pharmakokinetik, Biosimilars, Lebensqualität, Diabetes mellitus, Hypoglycemia, Insulin/pharmacokinetics, Biosimilar pharmaceuticals, Quality of life
Journal
INTERNIST
Volume 60, Issue 9, Pages 887-894
Publisher
Springer Science and Business Media LLC
Online
2019-08-08
DOI
10.1007/s00108-019-0652-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
- (2019) Jonas Kildegaard et al. PHARMACEUTICAL RESEARCH
- Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes
- (2018) Grit Andersen et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study
- (2018) Karl-Michael Derwahl et al. Diabetes Technology & Therapeutics
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
- (2018) Julio Rosenstock et al. DIABETES CARE
- Gestational Diabetes Mellitus (GDM) – Diagnosis, Treatment and Follow-Up. Guideline of the DDG and DGGG (S3 Level, AWMF Registry Number 057/008, February 2018)
- (2018) Ute Schäfer-Graf et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes
- (2017) Wendy Lane et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of glucose-responsive ‘smart’ insulin systems
- (2017) Nischay K. Rege et al. Current Opinion in Endocrinology Diabetes and Obesity
- Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
- (2016) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
- (2016) S. Garg et al. DIABETES OBESITY & METABOLISM
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
- (2015) Philip D. Home et al. DIABETES CARE
- Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
- (2015) T. C. Blevins et al. DIABETES OBESITY & METABOLISM
- Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi
- (2015) H. Yki-Järvinen et al. DIABETES OBESITY & METABOLISM
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- (2015) Tim Heise et al. Expert Opinion on Drug Metabolism & Toxicology
- Degludec: the new ultra-long insulin analogue
- (2015) Marcos Antonio Tambascia et al. Diabetology & Metabolic Syndrome
- New forms of insulin and insulin therapies for the treatment of type 2 diabetes
- (2015) Avivit Cahn et al. Lancet Diabetes & Endocrinology
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
- (2014) Matthew C. Riddle et al. DIABETES CARE
- Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
- (2014) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec
- (2013) Stefan Korsatko et al. CLINICAL DRUG INVESTIGATION
- Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial
- (2013) B. W. Bode et al. DIABETIC MEDICINE
- Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
- (2013) Tim Heise et al. Endocrine Practice
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase
- (2011) Marcus Hompesch et al. Diabetes Technology & Therapeutics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More